Clinical trials: Infiltrating Cervical Carcinoma
Nasopharyngeal Carcinoma
Phase II Trial of TIL Following CCRT in Patients With Locoregionally Advanced NPC
This is a Phase II trial to study the effectiveness and security of cisplatin concurrent chemoradiotherapy plus TIL versus cisplatin concurrent chemoradiotherapy only with IMRT in treating patients with locoregionally advanced…
- Trial name
- TIL (NCT02421640)
- Testing
- Cisplatin+TIL, Cisplatin
- Where
- China
- Volunteers
- 116 people
- Sponsor
- Sun Yat-sen University
Kita-kyushu Lung Cancer Antigen 1, Human
T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers
Background: Researchers have found a new way to treat cancer using T cell therapy. The therapy used in this study is T Cell Receptor (TCR) Gene Therapy Targeting Kita-Kyushu Lung Cancer Antigen-1 (KK-LC-1), a cancer germline…
- Trial name
- NCT05035407
- Testing
- IL-2 (Aldesleukin), Cyclophosphamide, KK-LC-1 TCR
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- National Cancer Institute (NCI)
Cervical Cancer
Evaluation of the Cancer Tracking System (CATSystem)
Cervical cancer contributes to significant preventable mortality in Kenya where less than 20% of women are screened. The Cancer Tracking System (CATSystem) is a web-based, algorithm generated tool to promote guideline adherent…
- Trial name
- CATSystem (NCT06286462)
- Testing
- Cancer Tracking System (CATSystem)
- Where
- 10 sites in Kenya
- Volunteers
- 6,600 people, healthy volunteers welcome
- Sponsor
- University of Kansas Medical Center
Cervical Carcinoma
Study of Tumor Infiltrating Lymphocytes Following CCRT in the Treatment of Patients With Cervical Carcinoma
A Phase I trial to evaluate the feasibility, toxicity and effectiveness of cisplatin concurrent chemoradiotherapy plus TIL in treating patients with FIGO stage IIIA to IVA cervical carcinoma.
- Trial name
- TIL-Cx (NCT04443296)
- Testing
- CCRT+TIL
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Sun Yat-sen University
Human Papilloma Virus, Cervical Cancer
Prevaccination Study of Cervical Human Papillomavirus Types in Yangtze River Delta Area, China
Human papilloma virus (HPV) infection contributes as a main causative factor to the development of invasive cervical cancer (ICC) and its precursors (cervical intraepithelial neoplasia, CIN).
- Conditions
- Human Papilloma Virus, Cervical Cancer, Cervical Intraepithelial Neoplasia
- Trial name
- NCT01487681
- Where
- China
- Volunteers
- 4,000 people
- Sponsor
- Xing Xie, MD
Adult
Autologous Tumor Infiltrating Lymphocytes (GT101 Injection) in Patients With Recurrent or Metastatic Cervical Cancer
This is a Phase II, multicenter, open-label, randomized, parallel group, treatment study to assess the efficacy and safety of Autologous Tumor Infiltrating Lymphocytes (GT101 injection) compared with Gemcitabine in participants…
- Trial name
- NCT06241781
- Testing
- GT101 injection, Gemcitabine injection
- Where
- 24 sites in China
- Volunteers
- 83 people
- Sponsor
- Grit Biotechnology
Women With Abnormal Pap Smears
A Non-Invasive Cervical Cancer Screening Modality: A Pilot Study
Cervix cancer is a major global health concern. A way to screen and immediately treat precancerous lesions (Screen-and-Treat) is greatly needed.
- Trial name
- NCT02767726
- Testing
- non-invasive multimodal imaging
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Advanced Solid Tumors, Non-Small Cell Lung Cancer
A Study of IOV-5001 in Adults With Advanced Solid Tumors
A Phase 1/2, multicenter, multi-cohort, open-label study of an autologous tumor-infiltrating lymphocytes (TIL) regimen with IOV-5001 in participants with previously treated advanced solid tumors
- Conditions
- Advanced Solid Tumors, Non-Small Cell Lung Cancer, Triple Negative Breast Cancer (TNBC), Colorectal Cancer
- Trial name
- NCT07743723
- Testing
- IOV-5001
- Where
- United States
- Volunteers
- 106 people
- Sponsor
- Iovance Biotherapeutics, Inc.
Cervical Cancer
Cervical Cancer Elimination -Using Implementation Science to Evaluate Deliver and Cost Introduction of Thermal Ablation
Global elimination of cervical cancer is a feasible goal; however, the countries with the greatest disease burden also have the greatest healthcare system challenges.
- Trial name
- TIBA (NCT05472311)
- Testing
- Thermal Ablation
- Where
- Kenya
- Volunteers
- 565 people, healthy volunteers welcome
- Sponsor
- University of Washington
Cervical Cancer
Cervical Cancer in French Guiana: Screening Between 2006-2011
Given that cervical cancer is the second most frequent cancer among women in french guiana the aim of the study was to determine the screening rate among women living in French Guiana.
- Trial name
- DepCol (NCT02903693)
- Testing
- cross sectional
- Where
- France
- Volunteers
- 91,458 people
- Sponsor
- Centre Hospitalier de Cayenne
Cervical Carcinoma
Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical Carcinoma
Prospective, multicenter, multiple cohort, open label, interventional study evaluating adoptive cell therapy (ACT) with autologous tumor infiltrating lymphocytes (TIL) infusion (LN-145), with or without pembrolizumab, followed by…
- Trial name
- NCT03108495
- Testing
- LN-145, LN-145 + pembrolizumab
- Where
- 43 sites in United States, France and 6 more
- Volunteers
- 210 people
- Sponsor
- Iovance Biotherapeutics, Inc.
Esophageal Squamous Cell Carcinoma
Changhai Multimodal Esophageal Cancer Cohort
The burden of esophageal squamous cell carcinoma (ESCC) in China is substantial, with 85% of the cancers being in the progressive stage.
- Trial name
- CMECC (NCT06410677)
- Testing
- DNA Sequencing, RNA Sequencing
- Where
- China
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Wangluowei
Cervical Intraepithelial Neoplasia, Invasive Cervical Cancer
Fenofibrate in Patients With Cervical Intraepithelial Neoplasia and Invasive Cervical Carcinoma
Normally, p53 helps prevent tumors from forming in the body. Early studies have shown that Fenofibrate, a cholesterol-lowering drug, can restore normal function to p53 and can change the metabolism of HPV-positive tumors in a way…
- Trial name
- NCT06191133
- Testing
- Fenofibrate, Cervical Conization, Hysterectomy
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Lindsay Ferguson, MD
High-Grade Squamous Intraepithelial Lesions
Preventing Invasive Cervical Cancer: The Importance of Expectant Management in Young Women With High-grade Pre-cancerous Lesions
Lesions classified as "High Grade Squamous Intra-epithelial Lesions" (HSIL) are pre-cervical lesions of the cervix, induced by infection with the Human Papilloma Virus (HPV).
- Trial name
- NCT03920800
- Testing
- Data extraction from medical files, Immunohistochemistry
- Where
- Belgium
- Volunteers
- 100 people
- Sponsor
- Catherine Vanpachterbeke
Cervical Cancer
Study of C-TIL052A Cell Therapy in Advanced Cervical Cancer
A study that aimed to assess the safety and anti-tumor activity of C-TIL052A cell therapy in subjects with persistent, recurrent and/or metastatic cervical cancer.
- Trial name
- TIL (NCT05475847)
- Testing
- Autologous Tumor Infiltrating Lymphocytes (C-TIL052A) Injection
- Where
- 2 sites in China
- Volunteers
- 20 people
- Sponsor
- Fudan University
Esophageal Squamous Cell Carcinoma (ESCC), Infiltration
Infiltration Pattern of Locally Advanced ESCC
Prospectively collect the pathological records of ESCC patients, and analyse the infiltration pattern of ESCC.
- Conditions
- Esophageal Squamous Cell Carcinoma (ESCC), Infiltration, Tumour
- Trial name
- NCT07567716
- Testing
- Esophagectomy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shanghai Chest Hospital
Metastatic Melanoma, Squamous Cell Carcinoma of the Head and Neck
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors
A prospective, open-label, multi-cohort, non-randomized, multicenter Phase 2 study evaluating adoptive cell therapy (ACT) with TIL [LN-144/LN-145 (lifileucel)] in combination with immune checkpoint inhibitors or TIL…
- Conditions
- Metastatic Melanoma, Squamous Cell Carcinoma of the Head and Neck, Non-small Cell Lung Cancer
- Trial name
- NCT03645928
- Testing
- Lifileucel, LN-145, Pembrolizumab
- Where
- 34 sites in United States, Canada and 5 more
- Volunteers
- 225 people
- Sponsor
- Iovance Biotherapeutics, Inc.
Locally Advanced Head and Neck Squamous Cell Carcinoma
Radiotherapy With Double Checkpoint Blockade of Locally Advanced HNSCC
First-line treatment of locally advanced HNSCC with double checkpoint blockade and radiotherapy dependent on intratumoral CD8+ T cell Infiltration.
- Trial name
- NCT03426657
- Testing
- Durvalumab + Tremelimumab + RT
- Where
- 7 sites in Germany
- Volunteers
- 120 people
- Sponsor
- University of Erlangen-Nürnberg Medical School